GTC Biotherapeutics (fka GTCB)

[DewDiligence]

||You suggested that GTC’s drug candidates have a greater likelihood of immunogenicity than recombinant drugs produced by other means.||
>I never once said anything close to that.<

I guess we disagree on what constitutes a suggestion. In msg #4256, you said:

“Lack of glycosylation can promote faster renal clearance, depending on the molecular weight of the protein. For AAT and Factor VII, their molecular weights fall into the range that makes me worry. In addition to my half-life concerns, some aglycosylated proteins (proteins that are normally glycosylated but manufactured in a non-glycosylated form) sometimes have a tendency to be more labile to proteolysis, aggregation, and immunogenicity.”